CliffBio
small molecule

TASIMELTEON

TASIMELTEON

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameTASIMELTEON
Active ingredientTASIMELTEON
Strength20MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2022
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.